Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer

BACKGROUND: Lenvatinib combined with anti-PD-1 antibodies and systemic chemotherapy has demonstrated a relatively high antitumor activity for intrahepatic cholangiocarcinoma in phase 2 clinical trials. However, its efficacy and safety in advanced biliary tract cancer (BTC) has not been reported in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Chengpei, Xue, Jingnan, Wang, Yunchao, Wang, Shanshan, Zhang, Nan, Wang, Yanyu, Zhang, Longhao, Yang, Xu, Long, Junyu, Yang, Xiaobo, Sang, Xinting, Zhao, Haitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889821/
https://www.ncbi.nlm.nih.gov/pubmed/36742297
http://dx.doi.org/10.3389/fimmu.2023.1109292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889821/
https://www.ncbi.nlm.nih.gov/pubmed/36742297
http://dx.doi.org/10.3389/fimmu.2023.1109292

Ejemplares similares